CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 16 enrolled
Drug / intervention
PF-07081532 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05745701
NCT05745701Phase 1Completed

A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO EVALUATE THE EFFECT OF ITRACONAZOLE AND CYCLOSPORINE ON THE SINGLE-DOSE PHARMACOKINETICS OF PF-07081532 IN OVERWEIGHT OR OBESE ADULT PARTICIPANTS

Pfizer·interventional·Posted Feb 27, 2023·Updated Sep 23, 2024

In Brief

A Phase 1 clinical trial evaluating PF-07081532, Cyclosporine, and 1 other intervention for Healthy. Completed, enrolled 16 participants across 1 site.

Detailed Summary

This is a Phase 1, open-label, fixed-sequence, 3-period study to evaluate the effect of multiple doses of itraconazole and a single dose of cyclosporine on the single-dose PK of PF-07081532 in otherwise healthy, overweight or obese, adult female and male participants. The 3 study periods will be conducted consecutively without a break.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
202420252026
First PostedFeb 27, 2023
Enrollment StartFeb 22, 2023
Primary CompletionMay 29, 2023
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 3.3 years ago

Interventions

PF-07081532drug

Oral Tablet

Cyclosporinedevice

Oral Solution

Itraconazoledrug

Oral Capsule